MRK Merck KGaA
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor; and strategic partnership with Versant Ventures to advance treatments for rare genetic cardiomyopathies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Merck (ETR: MRK)
›
Merck (ETR: MRK) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 61,949 employees.
The shares were at 148.30 EUR on 19 November 2026, up 28.2% over 52 weeks. Its 52-week range is 100.70 EUR to 156.25 EUR: the price is 5.1% below the high and 47.3% above the low.
At a market capitalisation of 64.52B EUR, it trades at 33.6 times trailing earnings and 16.3 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a premium of 36% for MRK. It pays a dividend yielding 1.46% (it pays out 50% of its earnings), against a median of 2.01% among the dividend payers in that peer group.
Merck reports return on equity of 9.1%, an operating margin of 17.0% and revenue up 5.8% year over year.
Its debt exceeds its cash by 7.72B EUR, a debt-to-equity ratio of 0.42. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 14 analysts cover the stock, with an average rating of Buy; their mean price target of 159.29 EUR is 7.4% above the current price. The next earnings report is expected on 4 March 2027.